283 related articles for article (PubMed ID: 30871078)
1. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
Rasche L; Kortüm KM; Raab MS; Weinhold N
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871078
[TBL] [Abstract][Full Text] [Related]
2. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
4. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
5. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
Kuroda J; Nagoshi H; Shimura Y; Taniwaki M
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207
[TBL] [Abstract][Full Text] [Related]
7. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.
Schürch CM; Rasche L; Frauenfeld L; Weinhold N; Fend F
Virchows Arch; 2020 Mar; 476(3):337-351. PubMed ID: 31848687
[TBL] [Abstract][Full Text] [Related]
8. Immunologic approaches for the treatment of multiple myeloma.
Rasche L; Weinhold N; Morgan GJ; van Rhee F; Davies FE
Cancer Treat Rev; 2017 Apr; 55():190-199. PubMed ID: 28431262
[TBL] [Abstract][Full Text] [Related]
9. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
10. Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic.
Morgan GJ; Rasche L
Expert Rev Hematol; 2018 Jul; 11(7):513-523. PubMed ID: 29944024
[TBL] [Abstract][Full Text] [Related]
11. [Multiple myeloma: pathophysiology and progress in management].
Kuroda J; Chinen Y
Rinsho Ketsueki; 2017; 58(5):487-497. PubMed ID: 28592764
[TBL] [Abstract][Full Text] [Related]
12. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
Glavey SV; Ghobrial IM
Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma, immunotherapy and minimal residual disease.
Kusenda J; Kovarikova A
Neoplasma; 2016; 63(5):651-8. PubMed ID: 27468868
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
19. The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.
Barth P; Vale C; Chambers AB; Reagan JL
Future Oncol; 2018 Aug; 14(19):1965-1976. PubMed ID: 30019947
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
